JP7850884B2 - 新規多重特異性抗体 - Google Patents
新規多重特異性抗体Info
- Publication number
- JP7850884B2 JP7850884B2 JP2023560715A JP2023560715A JP7850884B2 JP 7850884 B2 JP7850884 B2 JP 7850884B2 JP 2023560715 A JP2023560715 A JP 2023560715A JP 2023560715 A JP2023560715 A JP 2023560715A JP 7850884 B2 JP7850884 B2 JP 7850884B2
- Authority
- JP
- Japan
- Prior art keywords
- heavy chain
- seq
- amino acid
- acid sequence
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025179886A JP2026026084A (ja) | 2021-03-31 | 2025-10-24 | 新規多重特異性抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2027891 | 2021-03-31 | ||
| NL2027891 | 2021-03-31 | ||
| PCT/NL2022/050174 WO2022211625A1 (en) | 2021-03-31 | 2022-03-30 | Novel multispecific antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025179886A Division JP2026026084A (ja) | 2021-03-31 | 2025-10-24 | 新規多重特異性抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024511871A JP2024511871A (ja) | 2024-03-15 |
| JP7850884B2 true JP7850884B2 (ja) | 2026-04-24 |
Family
ID=76035095
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560715A Active JP7850884B2 (ja) | 2021-03-31 | 2022-03-30 | 新規多重特異性抗体 |
| JP2025179886A Pending JP2026026084A (ja) | 2021-03-31 | 2025-10-24 | 新規多重特異性抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025179886A Pending JP2026026084A (ja) | 2021-03-31 | 2025-10-24 | 新規多重特異性抗体 |
Country Status (13)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202105926QA (en) * | 2018-12-31 | 2021-07-29 | Merus Nv | Truncated multivalent multimers |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019009728A1 (en) | 2017-07-06 | 2019-01-10 | Merus N.V. | ANTIBODIES THAT MODULATE A BIOLOGICAL ACTIVITY EXPRESSED BY A CELL |
| WO2020038397A1 (en) | 2018-08-21 | 2020-02-27 | I-Mab | Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof |
| WO2020229626A1 (en) | 2019-05-14 | 2020-11-19 | F-Star Delta Limited | Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody |
| WO2020249071A1 (en) | 2019-06-12 | 2020-12-17 | Nanjing GenScript Biotech Co., Ltd. | Anti-pd-l1/anti-lag-3 multiple antigen binding proteins and methods of use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| TWI773646B (zh) * | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| EP3515951B1 (en) | 2016-09-23 | 2024-02-28 | Merus N.V. | Binding molecules that modulate a biological activity expressed by a cell |
| TWI917306B (zh) | 2017-07-06 | 2026-03-11 | 荷蘭商米樂斯股份有限公司 | 藉由細胞表現之調控生物活性的結合分子 |
-
2022
- 2022-03-30 CN CN202410306860.1A patent/CN118165116A/zh active Pending
- 2022-03-30 PH PH1/2023/552704A patent/PH12023552704A1/en unknown
- 2022-03-30 TW TW111112288A patent/TW202302630A/zh unknown
- 2022-03-30 KR KR1020237034870A patent/KR20230165256A/ko active Pending
- 2022-03-30 JP JP2023560715A patent/JP7850884B2/ja active Active
- 2022-03-30 EP EP22714634.7A patent/EP4314061A1/en active Pending
- 2022-03-30 CA CA3213796A patent/CA3213796A1/en active Pending
- 2022-03-30 BR BR112023020141A patent/BR112023020141A2/pt not_active Application Discontinuation
- 2022-03-30 US US18/553,114 patent/US20240309115A1/en active Pending
- 2022-03-30 IL IL307332A patent/IL307332A/en unknown
- 2022-03-30 WO PCT/NL2022/050174 patent/WO2022211625A1/en not_active Ceased
- 2022-03-30 AU AU2022251985A patent/AU2022251985A1/en active Pending
- 2022-03-30 MX MX2023011362A patent/MX2023011362A/es unknown
- 2022-03-30 CN CN202280026434.1A patent/CN117157323A/zh active Pending
-
2025
- 2025-10-24 JP JP2025179886A patent/JP2026026084A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019009728A1 (en) | 2017-07-06 | 2019-01-10 | Merus N.V. | ANTIBODIES THAT MODULATE A BIOLOGICAL ACTIVITY EXPRESSED BY A CELL |
| WO2020038397A1 (en) | 2018-08-21 | 2020-02-27 | I-Mab | Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof |
| WO2020229626A1 (en) | 2019-05-14 | 2020-11-19 | F-Star Delta Limited | Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody |
| WO2020249071A1 (en) | 2019-06-12 | 2020-12-17 | Nanjing GenScript Biotech Co., Ltd. | Anti-pd-l1/anti-lag-3 multiple antigen binding proteins and methods of use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118165116A (zh) | 2024-06-11 |
| JP2026026084A (ja) | 2026-02-16 |
| CA3213796A1 (en) | 2022-10-06 |
| AU2022251985A1 (en) | 2023-10-19 |
| PH12023552704A1 (en) | 2024-02-19 |
| JP2024511871A (ja) | 2024-03-15 |
| BR112023020141A2 (pt) | 2023-11-28 |
| MX2023011362A (es) | 2023-10-05 |
| KR20230165256A (ko) | 2023-12-05 |
| IL307332A (en) | 2023-11-01 |
| CN117157323A (zh) | 2023-12-01 |
| EP4314061A1 (en) | 2024-02-07 |
| US20240309115A1 (en) | 2024-09-19 |
| TW202302630A (zh) | 2023-01-16 |
| WO2022211625A1 (en) | 2022-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11161904B2 (en) | Anti-PD-1 antibody and use thereof | |
| US11472882B2 (en) | Anti-B7-H4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
| TWI866043B (zh) | 細胞毒性t淋巴球相關蛋白4(ctla-4)之新穎單株抗體 | |
| CN109843927B (zh) | 抗b7-h3抗体、其抗原结合片段及其医药用途 | |
| JP6755866B2 (ja) | Cd73特異的結合分子及びその使用 | |
| JP2022116257A (ja) | 癌の治療に用いるための細胞傷害誘導治療剤 | |
| JP7401166B2 (ja) | 抗btn3a抗体及びがん又は感染性障害の処置におけるその使用 | |
| JP2022526764A (ja) | EGFRxCD28多特異性抗体 | |
| US20240343803A1 (en) | Anti-Pvrig/Anti-Tigit Bispecific Antibodies And Applications Thereof | |
| WO2020098734A1 (zh) | 抗tigit抗体及其用途 | |
| US20250136687A1 (en) | Anti-human cd3 antibody and use thereof | |
| JP7843824B2 (ja) | 抗体および使用方法 | |
| US20250145705A1 (en) | Gprc5d antibody and application thereof | |
| KR20230051163A (ko) | Tigit 및 cd112r 차단 | |
| JP2026026084A (ja) | 新規多重特異性抗体 | |
| US20250297021A1 (en) | Bcma antibody and use thereof | |
| WO2023046113A1 (zh) | 一种抗人pd-l1人源化抗体或其抗原结合片段及其应用 | |
| US20240425595A1 (en) | Novel pd-1 binding domains | |
| US20220363761A1 (en) | Multispecific binding moieties comprising novel pd-1 binding domains | |
| JP2026508096A (ja) | 治療抗体 | |
| KR20250135354A (ko) | Baff-r 및 cd19에 특이적인 키메라 항원 수용체 및 그의 방법 및 용도 | |
| JP2024544386A (ja) | Pd-l1抗原結合タンパク質及びその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231221 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231221 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250421 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250624 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251024 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260113 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20260212 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260212 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260220 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7850884 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |